Browse CTHRC1

Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain -
Function

May act as a negative regulator of collagen matrix deposition.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0007164 establishment of tissue polarity
GO:0007423 sensory organ development
GO:0014020 primary neural tube formation
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0021915 neural tube development
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030278 regulation of ossification
GO:0032092 positive regulation of protein binding
GO:0033687 osteoblast proliferation
GO:0033688 regulation of osteoblast proliferation
GO:0033690 positive regulation of osteoblast proliferation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035567 non-canonical Wnt signaling pathway
GO:0042249 establishment of planar polarity of embryonic epithelium
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042490 mechanoreceptor differentiation
GO:0043393 regulation of protein binding
GO:0043583 ear development
GO:0043932 ossification involved in bone remodeling
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045778 positive regulation of ossification
GO:0046849 bone remodeling
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048771 tissue remodeling
GO:0048839 inner ear development
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060113 inner ear receptor cell differentiation
GO:0060119 inner ear receptor cell development
GO:0060122 inner ear receptor stereocilium organization
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0072175 epithelial tube formation
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090102 cochlea development
GO:0090103 cochlea morphogenesis
GO:0090175 regulation of establishment of planar polarity
GO:0090177 establishment of planar polarity involved in neural tube closure
GO:0090596 sensory organ morphogenesis
GO:0198738 cell-cell signaling by wnt
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005109 frizzled binding
GO:0017147 Wnt-protein binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CTHRC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CTHRC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CTHRC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4430.0395
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.9260.529
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0810.614
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6910.133
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6670.691
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7060.777
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4290.469
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.120.554
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3530.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4840.409
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.5860.339
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1080.674
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CTHRC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTHRC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTHRC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTHRC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTHRC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CTHRC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CTHRC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCTHRC1
Namecollagen triple helix repeat containing 1
Aliases Protein NMTC1; Collagen triple helix repeat-containing protein 1
Chromosomal Location8q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CTHRC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.